Section
Pipeline
Late-stage drugs with significant commercial implications
Pipeline
CS37’s single-dose gene editing could upend hemophilia B economics, but regulators and payers are watching lon…
Pipeline
As orforglipron and survodutide close in on approval, pharma faces a new pricing puzzle in the $80B obesity ma…
Pipeline
Lilly’s oral orforglipron and Boehringer’s survodutide aren’t just chasing Wegovy. Their late-stage data and p…
Pipeline
State pharmacy laws, not FDA designations, determine whether biosimilars actually get dispensed.…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.